SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02666755

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Novel Detection System for Detecting Epidermal Growth Factor Receptor Mutation in Plasma in Non-small Cell Lung Cancer

The purpose of this study is to investigate the sensitivity´╝îspecificity and concordance rate of EGFR testing results in plasma in comparison of results in matched tumor tissues tested by amplification refractory mutation system(ARMS). Moreover, the investigators correlate our findings in plasma with survival of advanced patients.

NCT02666755 Lung Neoplasms
MeSH:Lung Neoplasms
HPO:Neoplasm of the lung


Primary Outcomes

Description: comparing with results in tissues, tne investigators can get the sensitivity of results in plasma for Epidermal Growth Factor Receptor mutation in Non-small cell lung cancer.

Measure: sensitivity

Time: 2 years

Secondary Outcomes

Description: comparing with results in tissues, the investigators can get the specificity of results in plasma for Epidermal Growth Factor Receptor mutation in Non-small cell lung cancer.

Measure: specificity

Time: 2 years

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 T790M

Unfortunately, about 50%-60% patients who accept EGFR tyrosine kinase inhibitors with sensitizing mutations will receive resistance mutations, the T790M resistance is a target of active pharmaceutical development. --- T790M ---



HPO Nodes


HPO: